Hundreds of lawsuits have been filed against Takeda Pharmaceuticals Co. Ltd., the manufacturer of Actos®. Actos® has been the number one diabetes pill after Avandia® which was shown to sharply increase the risk of heart attacks. Taking the pill for more than a year however, has been shown to raise the risk of bladder cancer by 40%. The U.S. Food and Drug Administration has issued warnings about cancer risk based on new research, but sales have been allowed to continue. Doctors are currently being advised not to prescribe Actos® for people who have or have had bladder cancer.
The Judicial Panel on Multidistrict Litigation (JPML) on December 29, 2011 consolidated Actos cases to MDL No. 2299 assigned to Judge Rebecca F. Doherty in the U. S. District Court for the Western District of Louisiana. Showard Law Firm will be filing local claims directly in the MDL.
Track follow-ups from the FDA on approving updated drug labels for the pioglitazone-containing medicines to include safety information that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. Read more here.
The December 21, 2012, case management order in the Actos® MDL addressed the discovery protocol. The court is attempting to coordinate the discovery in the MDL with the various state court actions. The discovery in the Actos MDL is being overseen by deputy special masters Carmen M. Rodriguez and Kenneth W. DeJean.
If you or a loved one has taken Actos® and been diagnosed with bladder cancer contact Showard Law Firm at 622-3344 for a free consultation.
Trademark Notice: The use of the name of any product, including Actos®, is strictly for identification purposes in attorney advertising. Actos® is a registered trademark of Takeda Pharmaceuticals Co, Ltd. Showard Law firm is in no way affiliated with the manufacturer of an product referenced on this site, including Takeda Pharmaceuticals Co, Ltd.